BMXMFBiomerieux 69 Marcy L'Etoile

About Biomerieux 69 Marcy L'Etoile (BMXMF)

Biomerieux 69 Marcy L'Etoile (BMXMF) is a Diagnostics & Research company headquartered in Marcy l'Etoile, France whose shares trade over-the-counter on the Pink tier.

Biomerieux SA designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company's diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, or autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret the biological test results; and related services, such as the installation and maintenance of instruments, user training, or the audit of laboratory workflows. It offers diagnostic systems for clinical applications, including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples, such as blood, saliva, and urine; and for industrial applications, including the analysis of microbiological manufacturing, such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private-sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality-control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France.

BMXMF key facts

Ticker symbol

BMXMF

Market tier

Pink

Sector

Healthcare

Industry

Diagnostics & Research

Headquarters

Marcy l'Etoile, France

Country of incorporation

FR

Year of incorporation

2004

Employees

8,935

Reporting standard

International Reporting: Euronext Paris

Audit status

Audited

Fiscal year end

12/31

Explore more: Diagnostics & Research stocks · Healthcare sector · Pink stocks · OTC stocks starting with B